Sapana Supekar
by on April 9, 2021

Intravenous (IV) Solution Market Overview

Intravenous (IV) solutions are fluids that are intended to be injected directly into the venous circulation of individual patients who have deficiency in nutrients or suffer from serious cases of dehydration. The solutions are administered on to the patients whose body nutrients or fluid level falls beneath the standard requirement. These IV solutions are available in the market in various types for usage. Various companies provide packaged intravenous fluids or products to be mixed with sterile water in order to prepare a solution to be administered into the patient.

The global Intravenous (IV) solution market valuation is forecasted to reach USD 11,511.2 million by the end of the review period with a CAGR of 7.69% between 2016 and 2022. As mentioned previously, intravenous solutions are given to patients who are struggling with fluid volume level and deficiency of body nutrients. There are a number of reasons that can cause a drop in the fluid volume. Diarrhea and vomiting are two classic examples of the same, wherein individuals are encouraged to drink more fluids to balance out the electrolytes present in their body. Another cause of fluid volume can be blood loss. As they are consumed directly by the patient during such precarious situation, it is made under very strict regulations by the governments to ensure top-class results and constant availability at clinics, hospitals, and at home. The market demand for this product is surging ahead due to the rising prevalence of chronic diseases and a growing acceptance of Vitamin-C intravenous treatment therapy for treating colorectal cancer.

Intravenous (IV) Solution Market Segmentation

The global intravenous (IV) solution market is segmented in the following basis: type, end-users, and nutritional content.

By type, the market divides in to peripheral parenteral solution and total parenteral solution. With a market share of 66.9% in 2016, the total parenteral solution segment stood as the market dominator. The segment is expected to continue with its period of growth in the forthcoming years as well.

By nutritional content, the market holds carbohydrates, parental lipid emulsion, amino acid solution, vitamins & minerals, and others.

By end-users, the market includes ambulatory, home care, and hospitals and clinics. Hospitals and clinics segment tops the chart with over 40% of the market share under its belt, followed by ambulatory and home care segments, respectively. Both the ambulatory and home care segment will see rapid rise in terms of demand, however, hospitals and clinics segment is expected to hold on to its top position with continued growth and advancement.

Intravenous (IV) Solution Market Regional Analysis

The global intravenous (IV) solution market is growing at a steady pace. The regional market segmentation of intravenous (IV) solutions covers the following regions: Asia-Pacific, North America, Europe, and the Middle East & Africa.

As of 2015, North America held the largest market share of intravenous solutions. The regional market is expected to reach a market valuation of USD 6,543.4 million by the end of the forecast period at 2022. The growing market demand in this region can be attributed to factors such as the increasing acceptance of Vitamin C intravenous therapy treatment for colorectal cancer and the wide-spread prevalence of chronic diseases.

Europe holds the second spot in terms of the market share percentage and is expected to grow at desirable pace of 8.12% CAGR during the forecast period of 2016 to 2022. The Asia-Pacific regional market is believed to be fastest of the lot with a projected CAGR of 8.34% during the review period.

Browse Full Report with TOC at:

Intravenous (IV) Solution Market Competitive Landscape

The intravenous (IV) solution market includes various prominent and leading market players, the names of some of which are mentioned herein: Grifols S.A. (Spain), Fresenius Kabi AG (Germany), ICU Medical, Inc. (U.S.), Terumo Medical Corporation (Tokyo), B. Braun Melsungen AG (Germany), Baxter (U.S.), Amanta Healthcare (India), and others.

February 26th, 2019, Heron Therapeutics, a biotechnology company focused primarily on improving the lives of patients with their best-in-class and innovative treatment proceedings, announced in a statement that the FDA of the US has provided them with the approval for Heron’s supplemental NEW Drug Application for CINVANTI injectable emulsion, for IV usage.

Post in: Buisness, news, Health
Be the first person to like this.
Page generated in 0.316 seconds with 20 queries and GZIP enabled on